CL2014003243A1 - Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. - Google Patents

Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.

Info

Publication number
CL2014003243A1
CL2014003243A1 CL2014003243A CL2014003243A CL2014003243A1 CL 2014003243 A1 CL2014003243 A1 CL 2014003243A1 CL 2014003243 A CL2014003243 A CL 2014003243A CL 2014003243 A CL2014003243 A CL 2014003243A CL 2014003243 A1 CL2014003243 A1 CL 2014003243A1
Authority
CL
Chile
Prior art keywords
alkyltriazole
lpar
antagonists
compounds
pulmonary fibrosis
Prior art date
Application number
CL2014003243A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Deems Gabriel
Yimin Qian
Achyutharao Sidduri
Matthew Michael Hamilto0N
Matthew C Lucas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014003243A1 publication Critical patent/CL2014003243A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CL2014003243A 2012-06-20 2014-11-28 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. CL2014003243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20

Publications (1)

Publication Number Publication Date
CL2014003243A1 true CL2014003243A1 (es) 2015-03-20

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003243A CL2014003243A1 (es) 2012-06-20 2014-11-28 Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.

Country Status (22)

Country Link
US (1) US9321738B2 (enEXAMPLES)
EP (1) EP2864300A1 (enEXAMPLES)
JP (1) JP2015520202A (enEXAMPLES)
KR (1) KR20150021057A (enEXAMPLES)
CN (1) CN104411692A (enEXAMPLES)
AU (1) AU2013279512A1 (enEXAMPLES)
BR (1) BR112014030685A2 (enEXAMPLES)
CA (1) CA2869541A1 (enEXAMPLES)
CL (1) CL2014003243A1 (enEXAMPLES)
CO (1) CO7131358A2 (enEXAMPLES)
CR (1) CR20140525A (enEXAMPLES)
EA (1) EA201492285A1 (enEXAMPLES)
HK (1) HK1206342A1 (enEXAMPLES)
IL (1) IL236088A0 (enEXAMPLES)
IN (1) IN2014DN09348A (enEXAMPLES)
MA (1) MA37764A1 (enEXAMPLES)
MX (1) MX2014014710A (enEXAMPLES)
PE (1) PE20142448A1 (enEXAMPLES)
PH (1) PH12014502789A1 (enEXAMPLES)
SG (1) SG11201407220YA (enEXAMPLES)
UA (1) UA109868C2 (enEXAMPLES)
WO (1) WO2013189864A1 (enEXAMPLES)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
KR20150011389A (ko) * 2012-06-20 2015-01-30 에프. 호프만-라 로슈 아게 Lpar 길항제로서 n-아릴트라이아졸 화합물
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
KR102433588B1 (ko) 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
KR102697358B1 (ko) * 2017-12-19 2024-08-20 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산
MX2020005323A (es) * 2017-12-19 2020-08-13 Bristol Myers Squibb Co Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
WO2019126098A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
KR102725744B1 (ko) * 2017-12-19 2024-11-01 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 피라졸 아진
MX2020005818A (es) * 2017-12-19 2020-08-20 Bristol Myers Squibb Co Triazol azoles de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
ES2962367T3 (es) 2017-12-19 2024-03-18 Bristol Myers Squibb Co Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
JP7301840B2 (ja) 2017-12-19 2023-07-03 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸
AR113964A1 (es) * 2017-12-19 2020-07-01 Bristol Myers Squibb Co Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
WO2019126086A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
US11384055B2 (en) * 2017-12-29 2022-07-12 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
CN112702998A (zh) * 2018-09-18 2021-04-23 百时美施贵宝公司 作为lpa拮抗剂的环庚酸
EP3853232B1 (en) * 2018-09-18 2023-03-01 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
ES2946657T3 (es) 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN114728168B (zh) * 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7701473B2 (ja) 2021-05-11 2025-07-01 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
KR20240007233A (ko) * 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082A1 (en) 2021-12-08 2024-07-11 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
BR112013014019A2 (pt) * 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) * 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
WO2013189864A1 (en) 2013-12-27
MA37764A1 (fr) 2016-01-29
BR112014030685A2 (pt) 2017-06-27
SG11201407220YA (en) 2014-12-30
CA2869541A1 (en) 2013-12-27
HK1206342A1 (en) 2016-01-08
JP2015520202A (ja) 2015-07-16
KR20150021057A (ko) 2015-02-27
IN2014DN09348A (enEXAMPLES) 2015-07-17
PH12014502789A1 (en) 2015-02-09
IL236088A0 (en) 2015-02-01
CR20140525A (es) 2015-01-12
AU2013279512A1 (en) 2014-10-16
CO7131358A2 (es) 2014-12-01
EA201492285A1 (ru) 2015-04-30
US20150133511A1 (en) 2015-05-14
UA109868C2 (ru) 2015-10-12
CN104411692A (zh) 2015-03-11
EP2864300A1 (en) 2015-04-29
MX2014014710A (es) 2015-03-04
PE20142448A1 (es) 2015-01-28
US9321738B2 (en) 2016-04-26

Similar Documents

Publication Publication Date Title
CL2014003243A1 (es) Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar.
CL2014003241A1 (es) Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.
CL2014003242A1 (es) Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar.
IL277652A (en) Stable aqueous formulations of adlimumab
IL230913A0 (en) Lysophosphatidic acid receptor antagonists
EP2903509A4 (en) PORTABLE HEART MONITOR
DK2882850T3 (da) System for preparation of adipose-derived stem cells
CO7061086A2 (es) Combinaciones de compuestos activos
EP2925325A4 (en) STABILIZED FORMULATION OF PEMETREXED
CL2015001399A1 (es) Composiciones detergentes acuosas de estructura polimérica.
CO6970595A2 (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
IL237380A (en) Ethylene derivatives as modulators of mglur5 receptor activity
ZA201600753B (en) Amide derivatives as lysophosphatidic acid receptor antagonists
CR20140343A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
LT2782602T (lt) Nukleotidas dims0-150, skirtas lėtinio aktyvaus opinio kolito gydymui
PL2823052T3 (pl) Kompatybilna substancja rozpuszczona - ektoina, jak również jej pochodne do stabilizacji enzymów
ZA201500979B (en) Electrochemical generation of chlorinated urea derivatives
IL237217A0 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
IL237116A (en) Ethinyl derivatives as modulators of mglur5 receptor activity
FR2989199B1 (fr) Adaptateur electriquement actif
IL233939B (en) Liquid formulations of hypoglycemic sulfonamides
DK2900721T3 (da) Urethanalkyd, der omfatter stærke syregrupper
GB2532070B (en) Improvements relating to hypochlorous acid solutions
FR2989095B1 (fr) Clem2, retrotransposon actif des cafeiers